CD274 and neoplasm: The rationale for combining the selective MEK1 and MEK2 inhibitor cobimetinib with the PD-L1 blocking drug atezolizumab arose from the observation that MEK inhibition has positive immunomodulatory effects including intratumoral T cell accumulation and upregulation of MHC class I, potentially promoting antigen presentation and tumor immunogenicity.